Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (201-210 of 250) with videos related to

Pageof 25
Sort By:
Blood Cancer Discovery|April 15, 2025
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple MyelomaCamila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Blood|July 28, 2023
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Albert Oriol, Rafael Ríos, et al.
Nature Medicine|April 6, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trialFrancesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
Cancers|October 27, 2022
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical TrialJuan Manuel Rosa-Rosa, Isabel Cuenca, Alejandro Medina, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Pageof 25

Showing results (201-210 of 250) with videos related to

Sort By:
Pageof 25
Blood Cancer Discovery|April 15, 2025
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple MyelomaCamila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Blood|July 28, 2023
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Albert Oriol, Rafael Ríos, et al.
Nature Medicine|April 6, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trialFrancesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
The New England Journal of Medicine|December 9, 2014
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaA Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
Cancers|October 27, 2022
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical TrialJuan Manuel Rosa-Rosa, Isabel Cuenca, Alejandro Medina, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Blood Advances|December 7, 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialMeletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, et al.
Pageof 25